医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Exactech Announces First Surgery in the Middle East and Global Release of Next Generation GPS Shoulder

2023年05月31日 AM12:28
このエントリーをはてなブックマークに追加


 

GAINESVILLE, Fla.

Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced their first surgery in the United Arab Emirates earlier this month, which leveraged the company’s Active Intelligence® suite, using ExactechGPS® and the Equinoxe® Planning App. Exactech will celebrate the latest release of this GPS navigation software among more than 200 surgeons at their annual Shoulder Masters Course in Amsterdam later this week. The company will launch the updated software to surgeons in the EMEA and APAC regions following this groundbreaking operation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005473/en/

Exactech Announces First Surgery in the Middle East and Global Release of Next Generation GPS Shoulder (Photo: Exactech)

Exactech Announces First Surgery in the Middle East and Global Release of Next Generation GPS Shoulder (Photo: Exactech)

UAE-based British orthopaedic and trauma surgeon, Ved Goswami, MD, of Medclinic City Hospital, performed the reverse total shoulder arthroplasty using Exactech’s flagship navigation system with assistance by U.S. shoulder and elbow surgeon, Stephanie Muh, MD, of Henry Ford Health.

Dr. Goswami commented “ExactechGPS is designed to dramatically improve accuracy. The human eye allows implant placement by even the most experienced surgeons, to within 3 to 5 millimeters. However, with the guidance of GPS technology, more precise implant placement, within 1-2 mm, is possible.”

The U.S. release of v2.2 includes a new web upload feature, allowing surgeons and hospital staff to upload shoulder CT scans for reconstruction through the web. The EMEA and APAC release includes the following:

  • Upgrades to the user interface, visualization tools and additional views
  • Verification of final implant placement for reverse and anatomic shoulder procedures
  • Seamless integration with Exactech’s Ergo shoulder instrumentation
  • Wireless transmissions of case reports, including screenshots of steps and final implant placement, through the AI Surgeon dashboard

“By eliminating the capital purchase process, Exactech is democratizing data for orthopaedic surgeons all around the world with increased availability to powerful technologies that can help improve patient outcomes,” said Dr. Muh, an Exactech consultant who frequently engages in philanthropic travel to the UAE. “It’s exciting to see Exactech continue to bring this clinically beneficial technology to markets around the world.”

ExactechGPS is a foundational technology that powers Exactech’s Active Intelligence suite. The company steadily expands this portfolio of uniquely accessible smart solutions that support orthopaedic surgeons in and out of the operating room. For more information, visit www.AIExactech.com.

  1. Jones R. et al. Accuracy and precision of placement of the glenoid baseplate in reverse total shoulder arthroplasty using a novel computer assisted navigation system combined with preoperative planning: A controlled cadaveric study. JSES Seminars in Arthroplasty. 2020 May;30(1):73-82.*

*In vitro (bench) test results may not necessarily be indicative of clinical performance.

About Exactech

Exactech is a global medical device company that develops and markets orthopaedic implant devices, related surgical instruments and the Active Intelligence® platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Visit www.exac.com for more information and connect with us on LinkedIn, Vumedi, YouTube, Instagram and Twitter. With Exactech by your side, you’ve got EXACTLY what you need.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005473/en/

CONTACT

Sara Yun

Marketing Communications, OUS

Media@exac.com

同じカテゴリーの記事 

  • Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
  • エスリのテクノロジーをALS治療開発研究所が治験場所検索に採用
  • ALS Therapy Development Institute利用Esri技术绘制临床试验地图
  • Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
  • コルマーBNH、ヘモヒムの二重機能で国際競争力を強化